Go to the profile of Kalia Bernath-Levin
Kalia Bernath-Levin

Research Fellow, University of Western Australia

Go to the profile of Najoua Borkadi
Najoua Borkadi

Business Development Associate Director, University of Michigan

Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature

Go to the profile of Jenefer Thoroughgood
Jenefer Thoroughgood

Managing Director, Thoroughly Good Consulting

For nearly 20 years, I've worked in the digital media sector, with hands-on experience in editorial, marketing, sales and R&D. I'm passionate about engaging and understanding customers to develop great content and products. Formerly Chief Product & Customer Officer at Zapnito, I'm now an advisor to the company.
Icell Kealex Therapeutics is an oncology biotech startup based at JLABS at the Texas Medical Center in Houston, Texas. We are developing oncoloytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. This modification in the virus allows the tumor cells that are not infected with the virus to be target by T-cells. Icell Kealex has a deep pipeline of T cell engager oncolytic vaccinia virus which offer an advantage over other oncolytic viruses. We plan to enter phase 1 trials with our lead product in 2018. We are looking for co-development or licensing partnerships
Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

ValiSeek Limited was formed as a Joint Venture single asset company in 2014 to progress cancer program VAL401 through early stage clinical trials to a stage attractive for out-licensing. ValiSeek is looking to initiate detailed licensing discussions prior to completion for co-development or out-licensing on a regional, global or disease specific basis to ensure a smooth continuation of their project VAL401.
TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.